No Data
No Data
Tellgen Unit Gets License for Immunoassay Analyzers
Tellgen Corporation (300642.SZ): Jiangxi Tellgen fully automated chemiluminescence immunoassay analyzer obtained medical instrument registration certificate.
On July 15th, Gelunhui reported that Tellgen Corporation (stock code 300642.SZ) announced that its wholly-owned subsidiary, Jiangxi Tellgen Life Technology Co., Ltd. (hereinafter referred to as the 'subsidiary' or 'Jiangxi Tellgen') recently obtained a medical device registration certificate issued by the Jiangxi Provincial Drug Administration for a fully automated chemiluminescence immune analyzer (model, specification: TESMIi50, TESMIi50Pro). This product adopts the direct chemiluminescence method based on ester and matching detection reagents for qualitative or quantitative analysis of analytes in serum and plasma samples from the human body in clinical applications.
Tellgen Corporation (300642.SZ) shareholder Rongzhen Investment completed a shareholding reduction of 898,700 shares.
Tellgen Corporation (300642.SZ) announced that a specific shareholder, Shanghai Rongzhen Investment Group Co., Ltd. (hereinafter referred to as "shareholder"...)...
Perspective Life (300642.SZ): Medical Device Registration for the “Fully Automated Chemiluminescence Immunoanalyzer” was accepted
Toujing Life (300642.SZ) issued an announcement. Jiangxi Tuojing Life Technology Co., Ltd., a wholly-owned subsidiary of the company (“...
Perspective Life (300642.SZ): 2023 equity distribution, 10 distributions of 1.5 yuan, share registration date May 22
On May 15, Ge Longhui | Vision Life (300642.SZ) announced that the company's 2023 equity distribution plan is to distribute RMB 1.500,000 in cash (tax included) to all shareholders for every 10 shares based on the company's current total share capital excluding 162,180,091 shares after 1,946,150 shares have been repurchased. The share registration date for this equity distribution is May 22, 2024, and the ex-dividend date is May 23, 2024.
Insight Life (300642.SZ): Plans to increase capital in the holding subsidiary Maze Biotech
On May 14, Ge Longhui Life (300642.SZ) announced that due to biotechnology's business development needs, it plans to increase its registered capital from RMB 35 million to RMB 38.5 million. The total amount of capital increase is RMB 20 million. Shanghai Zhang Keling Yifan Venture Capital Center (limited partnership) and the company jointly pledged, and the rest of the shareholders relinquished their priority subscription rights. Among them: Zhang Ke Lingyi invested RMB 11 million to subscribe to Maxbiotech with an additional registered capital of RMB 1.925 million; the company invested RMB 9 million to subscribe to Maxim Biotech with an additional registered capital of 157
No Data